Want to see ALXO full AI Analyst Report?
ALX Oncology Holdings (ALXO) Stock Price & Analysis
ALXO Stock Chart & Stats
- Day’s Range
- $1.32 - $1.40
- 52-Week Range
- $0.86 - $2.66
- Previous Close
- $1.29
- Volume
- N/A
- Average Volume (3M)
- 1.49M
- Market Cap
- $178.38M
- Enterprise Value
- $153.58M
- Total Cash (Recent Filing)
- $138.23M
- Total Debt (Recent Filing)
- $9.71M
- Price to Earnings (P/E)
- ―
- Beta
- 0.92
- Next Earnings
- Mar 11, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Loss Improvement
The narrowing loss profile indicates some improvement in operating discipline or development efficiency, even though profitability remains distant. If sustained, lower losses could extend the company’s funding runway and reduce the amount of capital required to advance its oncology programs.
Low Leverage
Relatively modest debt gives ALX Oncology less fixed financial burden than a highly leveraged development company. This supports flexibility in allocating capital to research and clinical development, while reducing the immediate pressure from interest obligations as programs progress.
Clinical Pipeline Focus
A focused oncology platform centered on evorpacept, supported by additional early-stage programs, provides multiple potential avenues for development rather than reliance on a commercial product today. Advancement of this pipeline could create future partnership, milestone, or royalty opportunities.
Bears Say
No Commercial Revenue
Without recurring product revenue, ALX Oncology lacks an operating sales base to absorb research and corporate costs. Financial progress therefore depends heavily on clinical or regulatory advancement and the eventual creation of collaboration, licensing, or commercial revenue.
Persistent Cash Burn
Continued operating and free-cash-flow deficits show that the business must keep funding research and operations externally. Persistent burn can constrain development choices, increase dependence on financing conditions, and make any delay in program progress more financially consequential.
Shrinking Equity Cushion
A materially smaller equity base reduces the balance-sheet cushion available to support ongoing clinical development and operating losses. Combined with negative returns on equity, this raises the likelihood that future funding could be needed before a revenue inflection is achieved.
ALX Oncology Holdings News
ALX Oncology announces publication of data from ASPEN-06 Phase 2 trial
ALX Oncology (ALXO) announced the publication of clinical data from its ASPEN-06 randomized Phase 2 clinical trial in Nature Medicine. The Nature Medicine publication, titled “Evorpacept plus trastuzumab, ramucirumab and
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
What is ALX Oncology Holdings’s market cap?
When is ALX Oncology Holdings’s upcoming earnings report date?
How were ALX Oncology Holdings’s earnings last quarter?
Is ALX Oncology Holdings overvalued?
Does ALX Oncology Holdings pay dividends?
What is ALX Oncology Holdings’s EPS estimate?
How many shares outstanding does ALX Oncology Holdings have?
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ALX Oncology Holdings?
What is the TipRanks Smart Score and how is it calculated?
ALX Oncology Holdings Stock Smart Score
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jason Lettmann
- Employees
- 48
- Website
- www.alxoncology.com
- Address
- 323 Allerton Avenue, South San Francisco, CA, 94080, US
ALX Oncology Holdings (ALXO) Earnings & Revenues
ALXO Earnings Call
Earnings Call SentimentPositive
The call conveyed meaningful, reproducible efficacy signals for evorpacept combinations—especially in CD47-high, centrally confirmed HER2-positive patients—with durable responses across independent studies, a large evorpacept safety database, progressing second program (ALX2004), and strengthened corporate resources. However, the clinical findings are preliminary given small exploratory cohorts, CD47 assay/cutoff uncertainty, discordant HER2 testing, and anticipated need for a registrational trial, which introduces execution and regulatory risk. Overall, momentum and positive clinical signals outweigh the limitations, but important validation and prospective biomarker work remain.
View all ALXO earnings summariesALXO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 4 | 10 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 6 | 0 | 6 |
